Home
Market
Screener
Supply Chains
Search Company
Help
Learn

Home
Market
Screener
Supply Chains
Search Company
Help
Learn

More on Grace Therapeutics, Inc.

Valuation & fair value
Financial statements
Earnings (pre / post)
PEG ratio
PE ratio vs industry
Supply-chain map
Peer benchmarks
Options positioning
Institutional holders (13F)

Compare with peers

AKTX · Akari Therapeutics Plc
LLY · ELI LILLY & Co
BMYMP · Bristol-Myers Squibb Company PFD CONV 2
JNJ · JOHNSON & JOHNSON
ONC · BeOne Medicines Ltd.
ABBV · AbbVie Inc.

Explore

All stocks A–Z
Stocks by sector
Head-to-head comparisons
Browse 500+ stocks
Free DCF calculator
Stock screener
Supply-chain maps
Research & analysis

Stocks A–Z·Sectors·Developers·Pricing·Compare data APIs·30 years of statements in ChatGPT/Claude·DCF guide·DCF calculator·Market

EvidInvest is an independent research and information tool. Figures are calculated from public SEC filings and third-party market data and are provided for informational and educational purposes only. EvidInvest does not provide investment advice, brokerage, or financial services, and is not affiliated with any company it covers. Verify all figures against primary sources before making any decision.

Stock Lists

Growth Analysis - GRCE

Financial Metrics

Revenue Trends

Period:

CAGR Performance

Revenue

1Y GrowthN/A

5Y CAGRN/A

10Y CAGRN/A

Net Income

1Y GrowthN/A

5Y CAGRN/A

10Y CAGRN/A

EPS

1Y GrowthN/A

5Y CAGRN/A

10Y CAGRN/A

EBIT

1Y GrowthN/A

5Y CAGRN/A

10Y CAGRN/A

EBITDA

1Y GrowthN/A

5Y CAGRN/A

10Y CAGRN/A

Capex

1Y GrowthN/A

5Y CAGRN/A

10Y CAGRN/A

Equity

1Y Growth-4.07%

5Y CAGR2.80%

10Y CAGR11.06%

Cash Flow

1Y GrowthN/A

5Y CAGRN/A

10Y CAGRN/A

Historical CAGR

Year	1Y CAGR	2Y CAGR	3Y CAGR	5Y CAGR	10Y CAGR	15Y CAGR	20Y CAGR	30Y CAGR
FY 2026 Mar 31, 2026	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FY 2025 Mar 31, 2025	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FY 2024 Mar 31, 2024	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FY 2023 Mar 31, 2023	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FY 2022 Mar 31, 2022	50920.4%	N/A	N/A	N/A	64.1%	N/A	N/A	N/A
FY 2021 Mar 31, 2021	N/A	N/A	N/A	N/A	34.0%	N/A	N/A	N/A
FY 2020 Mar 31, 2020	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FY 2019 Mar 31, 2019	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FY 2018 Mar 31, 2018	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FY 2016 Mar 31, 2017	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FY 2017 Feb 28, 2017	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FY 2016 Feb 29, 2016	-87.2%	-75.2%	-66.0%	-0.9%	N/A	N/A	N/A	N/A
FY 2014 Feb 28, 2015	-52.0%	-44.7%	174.3%	N/A	N/A	N/A	N/A	N/A
FY 2013 Feb 28, 2014	-36.4%	555.6%	149.3%	N/A	N/A	N/A	N/A	N/A
FY 2012 Feb 28, 2013	6653.2%	393.6%	N/A	N/A	N/A	N/A	N/A	N/A
FY 2011 Feb 29, 2012	-63.9%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FY 2010 Feb 28, 2011	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FY 2009 Feb 28, 2010	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

More on Grace Therapeutics, Inc.

Valuation & fair value
Financial statements
Earnings (pre / post)
PEG ratio
PE ratio vs industry
Supply-chain map
Peer benchmarks
Options positioning
Institutional holders (13F)

Compare with peers

AKTX · Akari Therapeutics Plc
LLY · ELI LILLY & Co
BMYMP · Bristol-Myers Squibb Company PFD CONV 2
JNJ · JOHNSON & JOHNSON
ONC · BeOne Medicines Ltd.
ABBV · AbbVie Inc.

Explore

All stocks A–Z
Stocks by sector
Head-to-head comparisons
Browse 500+ stocks
Free DCF calculator
Stock screener
Supply-chain maps
Research & analysis

Stocks A–Z·Sectors·Developers·Pricing·Compare data APIs·30 years of statements in ChatGPT/Claude·DCF guide·DCF calculator·Market

Growth Analysis - GRCE

Financial Metrics

Revenue Trends

Period:

CAGR Performance

Revenue

1Y GrowthN/A

5Y CAGRN/A

10Y CAGRN/A

Net Income

1Y GrowthN/A

5Y CAGRN/A

10Y CAGRN/A

EPS

1Y GrowthN/A

5Y CAGRN/A

10Y CAGRN/A

EBIT

1Y GrowthN/A

5Y CAGRN/A

10Y CAGRN/A

EBITDA

1Y GrowthN/A

5Y CAGRN/A

10Y CAGRN/A

Capex

1Y GrowthN/A

5Y CAGRN/A

10Y CAGRN/A

Equity

1Y Growth-4.07%

5Y CAGR2.80%

10Y CAGR11.06%

Cash Flow

1Y GrowthN/A

5Y CAGRN/A

10Y CAGRN/A

Historical CAGR

Year	1Y CAGR	2Y CAGR	3Y CAGR	5Y CAGR	10Y CAGR	15Y CAGR	20Y CAGR	30Y CAGR
FY 2026 Mar 31, 2026	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FY 2025 Mar 31, 2025	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FY 2024 Mar 31, 2024	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FY 2023 Mar 31, 2023	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FY 2022 Mar 31, 2022	50920.4%	N/A	N/A	N/A	64.1%	N/A	N/A	N/A
FY 2021 Mar 31, 2021	N/A	N/A	N/A	N/A	34.0%	N/A	N/A	N/A
FY 2020 Mar 31, 2020	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FY 2019 Mar 31, 2019	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FY 2018 Mar 31, 2018	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FY 2016 Mar 31, 2017	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FY 2017 Feb 28, 2017	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FY 2016 Feb 29, 2016	-87.2%	-75.2%	-66.0%	-0.9%	N/A	N/A	N/A	N/A
FY 2014 Feb 28, 2015	-52.0%	-44.7%	174.3%	N/A	N/A	N/A	N/A	N/A
FY 2013 Feb 28, 2014	-36.4%	555.6%	149.3%	N/A	N/A	N/A	N/A	N/A
FY 2012 Feb 28, 2013	6653.2%	393.6%	N/A	N/A	N/A	N/A	N/A	N/A
FY 2011 Feb 29, 2012	-63.9%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FY 2010 Feb 28, 2011	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FY 2009 Feb 28, 2010	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A